alanine has been researched along with Gastric Diseases in 8 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujimoto, A | 1 |
| Uraoka, T | 1 |
| Nishizawa, T | 1 |
| Shimoda, M | 1 |
| Goto, O | 1 |
| Ochiai, Y | 1 |
| Maehata, T | 1 |
| Akimoto, T | 1 |
| Mitsunaga, Y | 1 |
| Sasaki, M | 1 |
| Yamamoto, H | 1 |
| Yahagi, N | 1 |
| Gagliano-Jucá, T | 1 |
| Moreno, RA | 1 |
| Zaminelli, T | 1 |
| Napolitano, M | 1 |
| Magalhães, AF | 1 |
| Carvalhaes, A | 1 |
| Trevisan, MS | 1 |
| Wallace, JL | 1 |
| De Nucci, G | 1 |
| Kinjo, N | 1 |
| Kawanaka, H | 1 |
| Akahoshi, T | 1 |
| Yamaguchi, S | 1 |
| Yoshida, D | 1 |
| Anegawa, G | 1 |
| Konishi, K | 1 |
| Tomikawa, M | 1 |
| Tanoue, K | 1 |
| Tarnawski, A | 1 |
| Hashizume, M | 1 |
| Maehara, Y | 1 |
| Naito, Y | 1 |
| Yoshikawa, T | 1 |
| Abasov, IT | 1 |
| Sakurai, K | 1 |
| Yamasaki, K | 1 |
| Watanabe, S | 1 |
| Wang, XE | 1 |
| Hirose, M | 1 |
| Yoshizawa, T | 1 |
| Iwazaki, R | 1 |
| Oide, H | 1 |
| Kitamura, T | 1 |
| Miwa, H | 1 |
| Miyazaki, A | 1 |
| Sato, N | 1 |
| Jacobi, CA | 1 |
| Ordemann, J | 1 |
| Zuckermann, H | 1 |
| Döcke, W | 1 |
| Volk, HD | 1 |
| Müller, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind Trial on the Gastrointestinal Integrity Evaluation After Daily Naproxen 1100 mg + Rebamipide 200mg for 7 Days Versus Naproxen 1100mg + Placebo for 7 Days[NCT02632812] | Phase 1 | 24 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Cryer score according to gastroduodenal mucosal injury:~0 = Normal or erythema~= Any amount of submucosal hemorrhage or edema without erosions~= 1 erosion +- submucosal hemorrhage or edema~= 2-4 erosions +- submucosal hemorrhage or edema~= 5 or more erosions and/or a single ulcer +- submucosal hemorrhage or edema~= Multiple ulcers +- submucosal hemorrhage or edema - Ulcer" (NCT02632812)
Timeframe: 8 days
| Intervention | Cryer score (Median) |
|---|---|
| Rebamipide & Naproxen | 4 |
| Placebo & Naproxen | 4 |
"Modified Lanza score according to gastroduodenal mucosal injury:~0 = No hemorrhage or erosion observed~= One or two hemorrhages or erosions observed in one gastric area~= Three to five hemorrhages or erosions observed in one gastric area~= Hemorrhages or erosions observed in two gastric areas, six or more hemorrhages or erosions observed in one gastric area, with the total number not exceeding ten in the entire stomach~= Hemorrhages or erosions observed in three or more gastric areas; eleven or more hemorrhages or erosions observed widely in the entire stomach~= Ulcer" (NCT02632812)
Timeframe: 8 days
| Intervention | Modified Lanza score (Median) |
|---|---|
| Rebamipide & Naproxen | 3.5 |
| Placebo & Naproxen | 4 |
(NCT02632812)
Timeframe: 60 days
| Intervention | adverse events (Number) |
|---|---|
| Rebamipide & Naproxen | 7 |
| Placebo & Naproxen | 7 |
"Histopathologic grade score developed for microscopic injury evaluation 0 = Normal gastric mucosa or mild chronic inflammation~= Chronic gastritis without activity~= Chronic gastritis with activity on antrum~= Chronic gastritis with activity on the body~= Chronic gastritis with activity on antrum and on the body" (NCT02632812)
Timeframe: 8 days
| Intervention | Histopathologic grade score (Median) | |
|---|---|---|
| Basal endoscopy | End of treatment endoscopy | |
| Placebo & Naproxen | 1 | 1 |
| Rebamipide & Naproxen | 1 | 1 |
Giemsa stain was used to diagnose H. pylori (positive = presence of H. pylori) (NCT02632812)
Timeframe: 8 days
| Intervention | participants (Number) | |
|---|---|---|
| Basal endoscopy | End of treatment endoscopy | |
| Placebo & Naproxen | 5 | 6 |
| Rebamipide & Naproxen | 5 | 6 |
Tissue prostaglandin concentration quantified by enzyme-linked immunosorbent assay (ELISA) using Cayman Chemical Monoclonal Prostaglandin E2 EIA Kit (item number 514010) (NCT02632812)
Timeframe: 8 days
| Intervention | pg/mL (mean tissue PGE2 concentration) (Mean) | |
|---|---|---|
| Basal PGE2 concentration | End of treatment PGE2 concentration | |
| Placebo & Naproxen | 1005 | 241 |
| Rebamipide & Naproxen | 999 | 168 |
1 review available for alanine and Gastric Diseases
| Article | Year |
|---|---|
Oxidative stress involvement and gene expression in indomethacin-induced gastropathy.
Topics: Alanine; Animals; Anti-Ulcer Agents; Apoptosis; DNA; Gastric Mucosa; Gene Expression Profiling; Gene | 2006 |
2 trials available for alanine and Gastric Diseases
| Article | Year |
|---|---|
Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial.
Topics: Adolescent; Adult; Alanine; Anti-Inflammatory Agents, Non-Steroidal; Dinoprostone; Double-Blind Meth | 2016 |
[Effect of alanyl-glutamine in postoperative total parenteral nutrition on postoperative immunosuppression and morbidity. Preliminary results of a prospective randomized study].
Topics: Adult; Aged; Alanine; Dipeptides; Esophageal Diseases; Female; Glutamine; Humans; Immune Tolerance; | 1998 |
5 other studies available for alanine and Gastric Diseases
| Article | Year |
|---|---|
Rebamipide solution: a novel submucosal injection material to promote healing speed and healing quality of ulcers induced by endoscopic submucosal dissection.
Topics: Alanine; Animals; Anti-Ulcer Agents; Endoscopic Mucosal Resection; Female; Fibrosis; Gastric Mucosa; | 2018 |
Significance of ERK nitration in portal hypertensive gastropathy and its therapeutic implications.
Topics: Alanine; Animals; Enzyme Inhibitors; Ethanol; Extracellular Signal-Regulated MAP Kinases; Gastric Mu | 2008 |
Chromatographic analysis of free amino acids of gastric juice in patients with cancer and other stomach diseases.
Topics: Adult; Alanine; Amino Acids; Arginine; Aspartic Acid; Chromatography; Cystine; Duodenal Ulcer; Femal | 1967 |
Protective effect of rebamipide against hydrogen peroxide-induced hemorrhagic mucosal lesions in rat stomach.
Topics: Alanine; Animals; Gastric Mucosa; Gastrointestinal Hemorrhage; Glutathione; Glutathione Peroxidase; | 1994 |
Effects of rebamipide on bile acid-induced inhibition of gastric epithelial repair in a rabbit cell culture model.
Topics: Actins; Alanine; Animals; Anti-Ulcer Agents; Bromodeoxyuridine; Cell Division; Cell Movement; Cells, | 1996 |